Genitourinary Cancers Symposium

If not, please take a few moments to fill out the form below. It’s free, and ensures that you receive regular alerts to the latest clinical news and other content.

Email*

Password*

Keep me logged in Forgot your password?

Email*

First Possible Drug Therapy for Angiomyolipoma Reported

Jody A. Charnow February 09, 2012

SAN FRANCISCO—Everolimus is the first potential pharmacologic treatment option for patients with angiomyolipoma (AML), a benign tumor that usually occurs in the kidney, researchers reported at the 2012 Genitourinary Cancers Symposium.

Immunotherapy May Improve mRCC Outcomes

John Schieszer February 08, 2012

SAN FRANCISCO—An immunotherapy (AGS-003) in combination with sunitinib may help prolong the lives of men with unfavorable risk, metastatic renal cell carcinoma (mRCC), according to new data from an open-label phase 2 study.

Bisphosphonates May Improve Outcomes in Patients with RCC and Bone Metastases

John Schieszer February 08, 2012

SAN FRANCISCO—Combining a bisphosphonate with sunitinib may improve progression-free survival (PFS) and overall survival (OS) in patients with bone metastases from renal cell carcinoma (RCC), that are treated with sunitinib, according to a multicenter, retrospective study presented at the 2012 Genitourinary Cancer Symposium.

Prior Sunitinib Duration Affects Second-Line RCC Therapy Outcomes

John Schieszer February 07, 2012

SAN FRANCISCO—Prior sunitinib treatment for nine months or longer may be associated with a longer progression-free survival (PFS) in patients with metastatic renal cell carcinoma (RCC) receiving axitinib as second-line treatment, according to a new study presented at the 2012 Genitourinary Cancer Symposium.

Circulating Tumor Cells Predict Worse Outcomes in Bladder Cancer Patients

Jody A. Charnow February 04, 2012

SAN FRANCISCO—The presence of circulating tumor cells (CTC) in the peripheral blood of patients with urothelial carcinoma of the bladder (UCB) prior to radical cystecomy are associated with worse disease outcomes, researchers reported here at the annual Genitourinary Cancers Symposium.

Similar Outcomes Found with Open, Robotic Cystectomy

Jody A. Charnow February 04, 2012

SAN FRANCISCO—Researchers who compared open and robotic cystectomy for bladder cancer found no significant difference in key outcomes after a median three years of follow-up, according to study findings presented here at the annual Genitourinary Cancers Symposium.

Never-Married Men Fare Worse After Prostate Cancer Surgery

Jody A. Charnow February 04, 2012

SAN FRANCISCO—Prostate cancer patients who have never been married are more likely than married men to die from their disease following radical prostatectomy (RP), according to study findings presented here at the annual Genitourinary Cancers Symposium.

Very Low Testosterone Hikes Prostate Cancer Recurrence Risk

Jody A. Charnow February 04, 2012

SAN FRANCISCO—Extremely low levels of testosterone in men after they have undergone radical prostatectomy (RP) for intermediate- to high-risk prostate cancer are associated with an elevated risk for biochemical recurrence of the disease, researchers reported here at the annual Genitourinary Cancers Symposium.

Brachytherapy May Be An Option for Men with High-Risk Prostate Cancer

Jody A. Charnow February 04, 2012

SAN FRANCISCO—Brachytherapy may be a treatment option for patients with high-risk prostate cancer (HRPC), according to data presented here at the annual Genitourinary Cancers Symposium.

Prostate Cancer Linked to Heavy Alcohol Intake

Jody A. Charnow February 03, 2012

SAN FRANCISCO—Heavy ethanol intake is associated with an increased risk of prostate cancer (PCa) among low-risk men with at least one prior negative prostate biopsy, investigators reported here at the annual Genitourinary Cancers Symposium. It also is associated with an elevated risk for high-grade PCa.

PSA Testing Rates Unchanged for Elderly Men Despite Task Force Guidelines

Jody A. Charnow February 03, 2012

SAN FRANCISCO—PSA testing rates for men aged 75 years and older did not decline despite a 2008 U.S. Preventive Services Task Force (USPSTF) recommendation against PSA screening for men in this age group, according to study findings presented at the annual Genitourinary Cancers Symposium.

Prostate Cancer Patients Far More Likely to Die from Other Causes

Jody A. Charnow February 03, 2012

SAN FRANCISCO—Elderly men who receive definitive local treatment for prostate cancer (PCa) are much more likely to die from causes other than their cancer, a finding that could inform doctor-patient discussions about treatment for localized PCa, investigators reported here at the annual Genitourinary Cancers Symposium.

Many Metastatic Prostate Cancers Go Untreated

Jody A. Charnow February 03, 2012

SAN FRANCISCO—Many patients with metastatic prostate cancer (PCa) never receive anticancer treatment, and older age, lower income, and lack of private health insurance may be among the reasons, according to data presented here at the annual Genitourinary Cancers Symposium.

Novel Drug Prolongs Survival in Men with Advanced Prostate Cancer

Jody A. Charnow February 03, 2012

SAN FRANCISCO—A novel medication may provide a new standard of care for the treatment of patients with castration-resistant prostate cancer (CRPC) and bone metastases, researchers reported here at the annual Genitourinary Cancers Symposium.

Herbal Product May Be Useful for Recurrent Prostate Cancer

Jody A. Charnow February 02, 2012

SAN FRANCISCO—A combination herbal supplement may benefit men with recurrent prostate cancer (PCa), according to a findings presented here at the annual Genitourinary Cancers Symposium.

First PSA Results Predict Long-Term Prostate Cancer Risk

Jody A. Charnow February 02, 2012

SAN FRANCISCO—PSA levels at the first date of testing may predict a man's long-term risk of prostate cancer and mortality in the general population, Danish investigators reported here at the annual Genitourinary Cancers Symposium.

Eating Rye Bread in Adolescence May Cut Prostate Cancer Risk

Jody A. Charnow February 02, 2012

SAN FRANCISCO—Greater rye bread consumption in adolescence may be associated with a decreased risk of prostate cancer, especially advanced disease, according to findings presented here at the annual Genitourinary Cancers Symposium.

Empiric Antibiotics for Elevated PSA of No Clinical Benefit

Jody A. Charnow February 02, 2012

SAN FRANCISCO—New findings presented here at the annual Genitourinary Cancers Symposium challenge the widespread practice of placing patients on an empiric course of antibiotics for a newly elevated PSA level.

Proton Therapy No Better than IMRT for Prostate Cancer

Jody A. Charnow February 02, 2012

SAN FRANCISCO—Proton therapy is no better than intensity modulated radiotherapy (IMRT) as a treatment for localized prostate cancer, and it is associated with greater gastrointestinal toxicities, researchers reported here at the Genitourinary Cancers Symposium.

Cost of RAPN vs. LPN Probed

John Schieszer April 21, 2011

ORLANDO—Robot-assisted partial nephrectomy (RAPN) has more upfront costs than laparoscopic partial nephrectomy (LPN), but these costs may decrease with time as surgeon and operating room staff experience increase, according to a new study.